MedTrace Logo

MESA Treatment for NK/T Cell Lymphoma

NCT01933282 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-12-24

No results posted yet for this study

Summary

Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma

Conditions

  • Lymphoma, Extranodal NK-T-Cell

Interventions

DRUG

MESA chemotherapy

Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5

DRUG

MESA

Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase

Sponsors & Collaborators

  • Air Force Military Medical University, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01933282 on ClinicalTrials.gov